APeT Holding

APeT (Advanced Peptide Therapeutics) is a Swiss biotechnology company dedicated to developing innovative peptide-based medicines for the treatment of ischemic diseases. The company's primary focus is on inhibiting Acid-Sensing Ion Channel 1a (ASIC1a), a critical mediator of tissue damage during stroke and heart attacks. Their lead candidate, APeT-1, is a potent and selective ASIC1a inhibitor derived from spider venom that has shown significant neuroprotective and cardioprotective potential in preclinical models. APeT aims to address the high unmet need for therapies that can preserve organ function following acute ischemic events. The company leverages research from the University of Queensland and the University of Zurich to advance its pipeline toward clinical trials.